STOCKHOLM - 7th SEPTEMBER, 2016. Dilaforette, a Karolinska Development (STO:KDEV) portfolio company focused on developing sevuparin, an innovative treatment for patients with sickle cell disease, announces CEO Christina Herder is to present at the 5th Annual Sickle-Cell Disease (SCD) Therapeutics Conference on 8th September 2016 in New York In her presentation, Dr Herder will outline Dilaforette’s development plans for sevuparin, a novel drug that it believes could offer a significant improvement of treatments in SCD. Sevuparin has the potential to normalize the lives of SCD patients, either by:
• Shortening hospital stays which result from an acute vaso-occlusive crisis (VOC); or
• Abolishing the need for hospitalization via patients being able to self-administer the drug when they believe a VOC is imminent
Dilaforette is currently enrolling SCD patients into a multi-centre, international, randomized Phase II study in Europe and the Middle East (NCT02515838).
Dr Herder’s presentation will take place at the Four Seasons Hotel in New York, USA. The presentation will begin at 14:40.
The Annual Sickle-Cell Disease Therapeutics Conference is a forum to discuss the latest advancements and future trends for treating patients with sickle-cell disease. The event will feature presentations from clinical-stage companies, key opinion leaders, patients and healthcare analysts.
For further information, please contact:
Christina Herder, CEO:
Tel: +46 70 374 71 56
E-mail: christina.herder@dilaforette.se
David Dible/ Pip Batty, Citigate Dewe Rogerson
Tel: +44 20 7638 9571
E-mail: david.dible@citigatedr.co.uk
